John Overdeck’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $408K | Buy |
+84,986
| New | +$373K | ﹤0.01% | 4314 |
|
|
2025
Q3 | – | Sell |
-11,299
| Closed | -$34.9K | – | 3631 |
|
|
2025
Q2 | $34.9K | Sell |
11,299
-6,987
| -38% | -$23.2K | ﹤0.01% | 3090 |
|
|
2025
Q1 | $63.8K | Sell |
18,286
-11,200
| -38% | -$37.4K | ﹤0.01% | 3019 |
|
|
2024
Q4 | $96.4K | Sell |
29,486
-240
| -0.8% | -$883 | ﹤0.01% | 2972 |
|
|
2024
Q3 | $114K | Buy |
29,726
+14,840
| +100% | +$56.9K | ﹤0.01% | 2885 |
|
|
2024
Q2 | $46K | Sell |
14,886
-83,030
| -85% | -$249K | ﹤0.01% | 2893 |
|
|
2024
Q1 | $253K | Sell |
97,916
-105,919
| -52% | -$274K | ﹤0.01% | 2625 |
|
|
2023
Q4 | $510K | Buy |
203,835
+178,523
| +705% | +$350K | ﹤0.01% | 2449 |
|
|
2023
Q3 | $51.4K | Sell |
25,312
-35,991
| -59% | -$75.5K | ﹤0.01% | 2812 |
|
|
2023
Q2 | $141K | Sell |
61,303
-308,474
| -83% | -$803K | ﹤0.01% | 2709 |
|
|
2023
Q1 | $1.12M | Buy |
+369,777
| New | +$1.04M | ﹤0.01% | 1803 |
|
|
2022
Q4 | – | Sell |
-24,442
| Closed | -$47K | – | 2768 |
|
|
2022
Q3 | $47K | Buy |
+24,442
| New | +$57.5K | ﹤0.01% | 2322 |
|
|
2022
Q2 | – | Sell |
-119,081
| Closed | -$355K | – | 2448 |
|
|
2022
Q1 | $355K | Sell |
119,081
-766,456
| -87% | -$2.35M | ﹤0.01% | 2157 |
|
|
2021
Q4 | $3.44M | Buy |
885,537
+155,239
| +21% | +$603K | 0.01% | 1461 |
|
|
2021
Q3 | $3.13M | Buy |
730,298
+476,475
| +188% | +$1.59M | 0.01% | 1578 |
|
|
2021
Q2 | $769K | Sell |
253,823
-515,228
| -67% | -$1.6M | ﹤0.01% | 2718 |
|
|
2021
Q1 | $2.56M | Buy |
+769,051
| New | +$2.97M | 0.01% | 1514 |
|
|
2020
Q3 | – | Sell |
-283,507
| Closed | -$516K | – | 3021 |
|
|
2020
Q2 | $516K | Buy |
283,507
+71,107
| +33% | +$116K | ﹤0.01% | 1980 |
|
|
2020
Q1 | $215K | Buy |
212,400
+121,536
| +134% | +$329K | ﹤0.01% | 2601 |
|
|
2019
Q4 | $253K | Buy |
90,864
+68,265
| +302% | +$110K | ﹤0.01% | 3299 |
|
|
2019
Q3 | $34K | Sell |
22,599
-65,507
| -74% | -$113K | ﹤0.01% | 3372 |
|
|
2019
Q2 | $183K | Buy |
88,106
+24,772
| +39% | +$63.4K | ﹤0.01% | 3111 |
|
|
2019
Q1 | $227K | Buy |
63,334
+10,990
| +21% | +$42.2K | ﹤0.01% | 2753 |
|
|
2018
Q4 | $200K | Buy |
52,344
+28,133
| +116% | +$139K | ﹤0.01% | 2712 |
|
|
2018
Q3 | $229K | Sell |
24,211
-48,503
| -67% | -$482K | ﹤0.01% | 2930 |
|
|
2018
Q2 | $531K | Buy |
+72,714
| New | +$433K | ﹤0.01% | 2601 |
|
|
2018
Q1 | – | Sell |
-42,665
| Closed | -$215K | – | 3082 |
|
|
2017
Q4 | $215K | Buy |
+42,665
| New | +$250K | ﹤0.01% | 2890 |
|
Other funds holding ABUS
TSC
WCM
RCMNY
John Overdeck's ABUS Position: Q2 2026 in Review
John Overdeck opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 84,986 shares worth $408K. The stake represents ﹤0.01% of the portfolio and ranks #4314 among its holdings. This is a return to the name: John Overdeck previously reported a position in ABUS as recently as Q2 2025.
John Overdeck first reported a position in ABUS in Q4 2017 and has held it in 27 quarters since. The position peaked at $3.44M in Q4 2021. 175 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.
- John Overdeck held 84,986 shares of Arbutus Biopharma worth $408K as of Q2 2026.
- Arbutus Biopharma was a new John Overdeck position in Q2 2026.
- Arbutus Biopharma made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4314 holding.
- John Overdeck first reported a position in Arbutus Biopharma in Q4 2017 and has held it in 27 quarters since.
- John Overdeck's Arbutus Biopharma position peaked at $3.44M in Q4 2021.
- 175 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.